-
1
-
-
79960530841
-
In vivo delivery of RNAi with lipid-based nanoparticles
-
Huang L, Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 2011;13:507-30.
-
(2011)
Annu Rev Biomed Eng
, vol.13
, pp. 507-530
-
-
Huang, L.1
Liu, Y.2
-
2
-
-
43549112555
-
Novel therapies for cancer: Why dirty might be better
-
Fojo T. Novel therapies for cancer: why dirty might be better. Oncologist 2008;13:277-83.
-
(2008)
Oncologist
, vol.13
, pp. 277-283
-
-
Fojo, T.1
-
3
-
-
77956901498
-
The promise of microRNA replacement therapy
-
Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010;70:7027-30.
-
(2010)
Cancer Res
, vol.70
, pp. 7027-7030
-
-
Bader, A.G.1
Brown, D.2
Winkler, M.3
-
4
-
-
58549114916
-
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells
-
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009;275:44-53.
-
(2009)
Cancer Lett
, vol.275
, pp. 44-53
-
-
Li, N.1
Fu, H.2
Tie, Y.3
Hu, Z.4
Kong, W.5
Wu, Y.6
-
5
-
-
77953920780
-
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells
-
Pang R, Leung C, Ye T, Liu W, Chiu P, Lam K, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010;31:1037-44.
-
(2010)
Carcinogenesis
, vol.31
, pp. 1037-1044
-
-
Pang, R.1
Leung, C.2
Ye, T.3
Liu, W.4
Chiu, P.5
Lam, K.6
-
6
-
-
34250868124
-
Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: MiR-34a is a p53 target that induces apoptosis and G1-arrest
-
Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-93.
-
(2007)
Cell Cycle
, vol.6
, pp. 1586-1593
-
-
Tarasov, V.1
Jung, P.2
Verdoodt, B.3
Lodygin, D.4
Epanchintsev, A.5
Menssen, A.6
-
7
-
-
34848868157
-
Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway inhuman colon cancer cells
-
Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway inhuman colon cancer cells. Proc Natl Acad Sci U S A 2007;104:15472-7.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 15472-15477
-
-
Tazawa, H.1
Tsuchiya, N.2
Izumiya, M.3
Nakagama, H.4
-
8
-
-
79751473114
-
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
-
Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.
-
(2011)
Nat Med
, vol.17
, pp. 211-215
-
-
Liu, C.1
Kelnar, K.2
Liu, B.3
Chen, X.4
Calhoun-Davis, T.5
Li, H.6
-
9
-
-
80052316514
-
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells
-
Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 2011;6:e24099.
-
(2011)
PLoS ONE
, vol.6
, pp. e24099
-
-
Nalls, D.1
Tang, S.N.2
Rodova, M.3
Srivastava, R.K.4
Shankar, S.5
-
10
-
-
53949090314
-
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
-
Ji Q, Xinbao Hao X, Meng Y, Zhang M, DeSano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008;8:266.
-
(2008)
BMC Cancer
, vol.8
, pp. 266
-
-
Ji, Q.1
Xinbao Hao, X.2
Meng, Y.3
Zhang, M.4
DeSano, J.5
Fan, D.6
-
11
-
-
84869083907
-
Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo
-
Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Müller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 2012;26:2421-4.
-
(2012)
Leukemia
, vol.26
, pp. 2421-2424
-
-
Craig, V.J.1
Tzankov, A.2
Flori, M.3
Schmid, C.A.4
Bader, A.G.5
Müller, A.6
-
12
-
-
77955022405
-
Development of a lung cancer therapeutic based on the tumor suppressor MicroRNA-34
-
Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor MicroRNA-34. Cancer Res 2010;70:5923-30.
-
(2010)
Cancer Res
, vol.70
, pp. 5923-5930
-
-
Wiggins, J.F.1
Ruffino, L.2
Kelnar, K.3
Omotola, M.4
Patrawala, L.5
Brown, D.6
-
13
-
-
84896049687
-
Aphase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
-
Tolcher AW, Rodrigueza WV, Rasco DW, Patnaik A, Papadopoulos KP, Amaya A, et al. Aphase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73:363-71.
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, pp. 363-371
-
-
Tolcher, A.W.1
Rodrigueza, W.V.2
Rasco, D.W.3
Patnaik, A.4
Papadopoulos, K.P.5
Amaya, A.6
-
14
-
-
65249154820
-
Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis
-
Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V, Benahmed AS, et al. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 2009;60:994-1005.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 994-1005
-
-
Andreakos, E.1
Rauchhaus, U.2
Stavropoulos, A.3
Endert, G.4
Wendisch, V.5
Benahmed, A.S.6
-
15
-
-
0346094457
-
Prediction of Mammalian MicroRNA targets
-
Lewis BP, Shih I-h, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of Mammalian MicroRNA targets. Cell 2003;115:787-98.
-
(2003)
Cell
, vol.115
, pp. 787-798
-
-
Lewis, B.P.1
Shih, I.-H.2
Jones-Rhoades, M.W.3
Bartel, D.P.4
Burge, C.B.5
-
16
-
-
77956627711
-
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
-
Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
-
(2010)
Oncogene
, vol.29
, pp. 4989-5005
-
-
Whittaker, S.1
Marais, R.2
Zhu, A.X.3
-
17
-
-
84866259297
-
Molecular mechanisms of liver injury and hepatocarcinogenesis: Focusing on the role of stress-activated MAPK
-
172894
-
Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int 2012;172894:1-14.
-
(2012)
Patholog Res Int
, pp. 1-14
-
-
Nakagawa, H.1
Maeda, S.2
-
18
-
-
84870518210
-
Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development
-
Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 2012;56:2255-67.
-
(2012)
Hepatology
, vol.56
, pp. 2255-2267
-
-
Wu, K.1
Ding, J.2
Chen, C.3
Sun, W.4
Ning, B.F.5
Wen, W.6
-
19
-
-
0026459290
-
p53 gene mutation spectrum in hepatocellular carcinoma
-
Oda T, Tsuda H, Scarpa A, Sacamoda M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;62:6358-64.
-
(1992)
Cancer Res
, vol.62
, pp. 6358-6364
-
-
Oda, T.1
Tsuda, H.2
Scarpa, A.3
Sacamoda, M.4
Hirohashi, S.5
-
20
-
-
80054978000
-
Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis
-
Walker MR, Makropoulos DA, Achuthanandam R, Vaan Arsdell S, Bugelski P. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis. Int Immunopharmacol 2011;11:1697-705.
-
(2011)
Int Immunopharmacol
, vol.11
, pp. 1697-1705
-
-
Walker, M.R.1
Makropoulos, D.A.2
Achuthanandam, R.3
Vaan Arsdell, S.4
Bugelski, P.5
-
22
-
-
84861912234
-
Targeted therapy in hepatocellular carcinoma
-
Chua CW, Choo SP. Targeted therapy in hepatocellular carcinoma. Int J Hepatol 2011;2011:1-11.
-
(2011)
Int J Hepatol
, vol.2011
, pp. 1-11
-
-
Chua, C.W.1
Choo, S.P.2
-
23
-
-
84155180680
-
Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss
-
Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology 2012;55:121-31.
-
(2012)
Hepatology
, vol.55
, pp. 121-131
-
-
Morris, S.M.1
Baek, J.Y.2
Koszarek, A.3
Kanngurn, S.4
Knoblaugh, S.E.5
Grady, W.M.6
-
24
-
-
57749116172
-
Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215
-
Georges SA. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 2008;68:10105-12.
-
(2008)
Cancer Res
, vol.68
, pp. 10105-10112
-
-
Georges, S.A.1
-
25
-
-
84883743256
-
TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.)
-
Zhao J, Lammers P, Torrance CJ, Bader AG. TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther 2013;21:1678-86.
-
(2013)
Mol Ther
, vol.21
, pp. 1678-1686
-
-
Zhao, J.1
Lammers, P.2
Torrance, C.J.3
Bader, A.G.4
-
26
-
-
84864926277
-
New insights into p53 signaling and cancer cell response to DNA damage: Implications for cancer therapy
-
Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol 2012;2012:170325.
-
(2012)
J Biomed Biotechnol
, vol.2012
, pp. 170325
-
-
Mirzayans, R.1
Andrais, B.2
Scott, A.3
Murray, D.4
-
27
-
-
70450228519
-
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells
-
Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 2009;8:90.
-
(2009)
Mol Cancer
, vol.8
, pp. 90
-
-
Yuzugullu, H.1
Benhaj, K.2
Ozturk, N.3
Senturk, S.4
Celik, E.5
Toylu, A.6
-
28
-
-
55249106920
-
Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology
-
Cavard C, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, et al. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol 2008;4:647-60.
-
(2008)
Future Oncol
, vol.4
, pp. 647-660
-
-
Cavard, C.1
Colnot, S.2
Audard, V.3
Benhamouche, S.4
Finzi, L.5
Torre, C.6
-
29
-
-
77954119208
-
Molecular and functional genetics of hepatocellular carcinoma
-
Yam JW, Wong CM, Ng IO. Molecular and functional genetics of hepatocellular carcinoma. Front Biosci (Schol Ed) 2010;2:117-34.
-
(2010)
Front Biosci(Schol Ed)
, vol.2
, pp. 117-134
-
-
Yam, J.W.1
Wong, C.M.2
Ng, I.O.3
-
30
-
-
33751530490
-
Mining the Wnt pathway for cancer therapeutics
-
Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 997-1014
-
-
Barker, N.1
Clevers, H.2
-
31
-
-
67650230896
-
Wnt/beta-catenin signaling: Components, mechanisms, and diseases
-
MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
-
(2009)
Dev Cell
, vol.17
, pp. 9-26
-
-
MacDonald, B.T.1
Tamai, K.2
He, X.3
-
32
-
-
2542473135
-
Overexpression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis
-
Huynh H, Nguyen TTT, Chow K-H P, Tan PH, Soo KC, Tran E. Overexpression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003;3:19.
-
(2003)
BMC Gastroenterol
, vol.3
, pp. 19
-
-
Huynh, H.1
Nguyen, T.T.T.2
Chow, K.-H.P.3
Tan, P.H.4
Soo, K.C.5
Tran, E.6
-
33
-
-
67749117934
-
Signal integration by JNK and p38 MAPK pathways in cancer development
-
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Cancer Rev 2009;9:537-49.
-
(2009)
Nat Cancer Rev
, vol.9
, pp. 537-549
-
-
Wagner, E.F.1
Nebreda, A.R.2
-
34
-
-
64549120305
-
Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells
-
Cheng WT, Xu K, Tian DY, Zhang ZG, Liu LJ, Chen Y. Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int J Oncol 2009;34:829-36.
-
(2009)
Int J Oncol
, vol.34
, pp. 829-836
-
-
Cheng, W.T.1
Xu, K.2
Tian, D.Y.3
Zhang, Z.G.4
Liu, L.J.5
Chen, Y.6
-
35
-
-
84860709668
-
Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway
-
Lu J-t, Zhao W-d, He W, Wei W. Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway. Acta Pharmacol Sin 2012;33:691-700.
-
(2012)
Acta Pharmacol Sin
, vol.33
, pp. 691-700
-
-
Lu, J.-T.1
Zhao, W.-D.2
He, W.3
Wei, W.4
-
36
-
-
84863264746
-
A polymeric nanoparticle encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma
-
Xu Y, Chenna V, Hu C, Sun HX, Khan M, Bai H, et al. A polymeric nanoparticle encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2012;18:1291-302.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1291-1302
-
-
Xu, Y.1
Chenna, V.2
Hu, C.3
Sun, H.X.4
Khan, M.5
Bai, H.6
-
37
-
-
33645371509
-
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis
-
Sicklick JK, Li Y-X, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006;27:748-57.
-
(2006)
Carcinogenesis
, vol.27
, pp. 748-757
-
-
Sicklick, J.K.1
Li, Y.-X.2
Jayaraman, A.3
Kannangai, R.4
Qi, Y.5
Vivekanandan, P.6
-
38
-
-
80051728375
-
Future treatment option for hepatocellular carcinoma: A focus on brivanib
-
Kudo M. Future treatment option for hepatocellular carcinoma: a focus on brivanib. Dig Dis 2011;29:316-20.
-
(2011)
Dig Dis
, vol.29
, pp. 316-320
-
-
Kudo, M.1
-
39
-
-
33644921213
-
VEGF in hepatocellular carcinoma and surrounding cirrhotic liver tissues
-
Mathonnet M, Descottes B, Valleix D, Labrousse F, Denizot Y. VEGF in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2006;12:830-1.
-
(2006)
World J Gastroenterol
, vol.12
, pp. 830-831
-
-
Mathonnet, M.1
Descottes, B.2
Valleix, D.3
Labrousse, F.4
Denizot, Y.5
-
40
-
-
67650305795
-
Targeting angiogenesis in hepatocellular carcinoma: Focus on VEGF and bevacizumab
-
Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009; 9:503-9.
-
(2009)
Expert Rev Anticancer Ther
, vol.9
, pp. 503-509
-
-
Finn, R.S.1
Zhu, A.X.2
-
41
-
-
70350507211
-
Vascular endothelial growth factor in the management of hepatocellular carcinoma: A review of literature
-
Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009;115:4895-906.
-
(2009)
Cancer
, vol.115
, pp. 4895-4906
-
-
Kaseb, A.O.1
Hanbali, A.2
Cotant, M.3
Hassan, M.M.4
Wollner, I.5
Philip, P.A.6
-
42
-
-
0030951358
-
Expression of hepatocyte growth factor and its receptor c-met proto-oncog
-
Ueki T, Fujimoto J, Suzuki T, Yamimoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncog. Hepatology 1997;25:862-6.
-
(1997)
Hepatology
, vol.25
, pp. 862-866
-
-
Ueki, T.1
Fujimoto, J.2
Suzuki, T.3
Yamimoto, H.4
Okamoto, E.5
-
43
-
-
79955952335
-
Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib
-
Porta C, Paglino C. Medical treatment of unresectable hepatocellular carcinoma: going beyond sorafenib. World J Hepatol 2010;2:103-13.
-
(2010)
World J Hepatol
, vol.2
, pp. 103-113
-
-
Porta, C.1
Paglino, C.2
-
44
-
-
0037442149
-
Current treatment for liver metastases from colorectal cancer
-
Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 2003;9:193-200.
-
(2003)
World J Gastroenterol
, vol.9
, pp. 193-200
-
-
Liu, L.X.1
Zhang, W.H.2
Jiang, H.C.3
|